Sunshine Biopharma, Inc.
SBFM
$2.18
$0.041.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.09M | 8.58M | 9.42M | 9.41M | 8.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.09M | 8.58M | 9.42M | 9.41M | 8.90M |
| Cost of Revenue | 5.91M | 5.55M | 6.34M | 5.99M | 6.17M |
| Gross Profit | 2.18M | 3.03M | 3.07M | 3.42M | 2.73M |
| SG&A Expenses | 3.34M | 4.39M | 3.27M | 4.03M | 3.64M |
| Depreciation & Amortization | 76.90K | 98.90K | 95.80K | 72.50K | 64.80K |
| Other Operating Expenses | 129.70K | 126.50K | 119.90K | 112.70K | 110.20K |
| Total Operating Expenses | 9.48M | 10.24M | 9.95M | 10.40M | 10.20M |
| Operating Income | -1.40M | -1.66M | -532.00K | -992.80K | -1.30M |
| Income Before Tax | -1.24M | -1.73M | -1.02M | -1.98M | -1.22M |
| Income Tax Expenses | -- | 408.40K | -137.40K | -209.20K | -40.20K |
| Earnings from Continuing Operations | -1.24M | -2.14M | -883.80K | -1.77M | -1.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.24M | -2.14M | -883.80K | -1.77M | -1.18M |
| EBIT | -1.40M | -1.66M | -532.00K | -992.80K | -1.30M |
| EBITDA | -1.32M | -1.56M | -435.80K | -920.30K | -1.23M |
| EPS Basic | -2.54 | -4.85 | -2.13 | -4.33 | -4.36 |
| Normalized Basic EPS | -1.58 | -2.27 | -0.69 | -1.40 | -2.82 |
| EPS Diluted | -2.54 | -4.85 | -2.13 | -4.33 | -4.36 |
| Normalized Diluted EPS | -1.58 | -2.27 | -0.69 | -1.40 | -2.82 |
| Average Basic Shares Outstanding | 490.60K | 5.34M | 5.01M | 4.95M | 270.30K |
| Average Diluted Shares Outstanding | 490.60K | 5.34M | 5.01M | 4.95M | 270.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |